[A22-08] Vericiguat (cardiac failure) - Addendum to Commission A21-120

Last updated 03.03.2022

Project no.:

Commission awarded on 25.01.2022 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Heart and circulation


Adults with symptomatic chronic heart failure with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy

Result of dossier assessment:

Unchanged after addendum:

  • Age < 75 years: hint of a non-quantifiable added benefit
  • Age ≥ 75 years: added benefit not proven

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-03-03 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form